CGRP drugs in pregnancy

A new report suggests that CGRP-blocking drugs (CGRP-A) are safe in pregnancy.

In the latest study, Swiss doctors examined the World Health Organization’s pharmacovigilance database and looked at reporting differences between CGRP drugs and triptans.

Triptans (drugs like sumatriptan or Imitrex and six others) were introduced over 30 years ago.  We know from pregnancy registries, retrospective, and prospective observational studies that triptans are safe in pregnancy.

The WHO database had 467 safety reports of exposure to CGRP-A in pregnancy. Of these, 386 were reports of exposure to CGRP monoclonal antibodies (mAbs), 76 to gepants, and 5 to both. The authors found “…no signals of increased reporting with CGRP-A compared to triptans in relation to pregnancy”.

CGRP drugs represent a major breakthrough in treating migraine headaches. A large proportion of migraine sufferers are women of childbearing age. We always have to consider the effect of a drug on the developing fetus. Erenumab (Aimovig), the first drug in this category was introduced almost six years ago. This is a relatively short period to assess the safety of a drug in pregnant women and the current report is not a definitive proof of safety.

There might be a difference in safety between oral CGRP antagonists (gepants), which are small molecules and injectable mAbs, which are large molecules. Gepants have the advantage of being completely washed out of the body within a few days of stopping them.  Monoclonal antibodies are injected every one or three months and can take a few months to completely leave the body. However, mAbs, being larger, cannot cross the placenta in the first trimester. So if a mAb is stopped at the beginning of pregnancy the exposure to the fetus will be small.

The gepants include ubrogepant (Ubrelvy), rimegepant (Nurtec), atogepant (Qulipta), and a nasal spray, zavegepant (Zavzpret). The monoclonal antibodies are erenumab, fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti).

7 comments
  1. Dr. Mauskop says: 07/04/20245:32 pm

    There is little data about pregnancy outcomes in women who became pregnant while taking Ubrelvy. So far, Ubrelvy and similar drugs appear safe.

  2. Jaime says: 07/04/20242:07 pm

    Took Ubrevly during the first 3-4 weeks of gestation. I am very worried about exposure and there is o data. any thoughts?

  3. Christina says: 04/07/20247:49 pm

    What is your opinion on these drugs and breastfeeding? Since they are large molecules (Emgality specifically), would they be safe for nursing? I’m currently nursing my toddler still and my neurologist has advised that Emgality should be safe. But given the lack of data, I’m still hesitant.

  4. Emily says: 03/13/20244:17 am

    Dear dr. Mauskop, I would like to add a question to the comment that was made above. I am a CBT therapist and I have a patient that is on Amovig and is experiencing anxiety. I wanted to ask in your experiences can anxiety/depression induced by CGRP be treated with CBT/mindfulness technices ? My clients headache started once he stopped with Paxil 6 month ago. The timing could be a coincidence, but I thought it was worth to mention.

  5. Anuša says: 03/12/20244:50 pm

    Thank you so much for your answer.

  6. Dr. Mauskop says: 03/11/202412:49 pm

    It is very uncommon, but I have seen CGRP drugs cause anxiety or depression. And yes, we often combine CGRP drugs and antidepressants.

  7. Anuša says: 03/11/202412:21 pm

    Thank you for this interesting post, I will however ask an intermezzo question. My husband is on ajovy but he is experiencing anxiety since on it. Do you find that common in your practice ? Is it safe to take antidepressants while on cgrp ?

Submit comment